Telix Pharmaceuticals Limited
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christian Behrenbruch
- Full Time Employees
- 415
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 55 Flemington Road North Melbourne VIC Australia 3051
- IPO Date
- Jul 25, 2019
- CIK
- 0002007191
- Website
- telixpharma.com
- Similar Companies
- Business
- Telix Pharmaceuticals Limited (TLPPF) is a biopharmaceutical company focused on the development and commercialization of targeted radiopharmaceuticals for the treatment of cancer and rare diseases. The company offers a portfolio of products and services including Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection), a prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging agent approved for detecting prostate cancer recurrence and metastases; TLX591, a therapeutic antibody targeting PSMA for prostate cancer treatment; TLX101-CDx, a PET imaging agent for glioblastoma; and a pipeline of investigational radiopharmaceuticals such as TLX250-CDx for renal cell carcinoma imaging and TLX66 for radiotherapy applications. Its offerings encompass diagnostic imaging agents, targeted therapies, and companion diagnostics across oncology and rare disease segments, serving healthcare providers, nuclear medicine facilities, and patients primarily in North America, Europe, and Australia. Founded in 2015 and headquartered in Melbourne, Australia, Telix operates globally with subsidiaries in the United States, Europe, and Switzerland, emphasizing theranostic approaches that combine diagnostics and therapeutics.
Telix Seeks Reset With FDA Filing While Sales Growth Holds Steady
Telix Pharmaceuticals: Solid Q1 As Pipeline And PSMA Franchise Drive Outlook
Why Is Telix Pharma Stock Soaring Tuesday?
Telix Pharmaceuticals (OTCMKTS:TLPPF) Shares Down 5.3% – Time to Sell?
Telix Pharmaceuticals Limited (TLX) Discusses Revenue Growth, Prostate Cancer Imaging Portfolio, and Expansion into Brain and Kidney Cancer Transcript
Telix Pharmaceuticals Limited (TLX) Discusses ProstACT Global Phase 3 Study Part 1 Results and Safety Profile Transcript
Telix Pharmaceuticals Limited (TLX) Discusses Physician Perspectives on Innovations in PSMA PET CT Imaging for Prostate Cancer Transcript
Telix Pharmaceuticals: Scope Of Company Beyond Radio Antibody-Drug Conjugate TLX591-Tx
Telix Pharmaceuticals Limited (TLX) Q4 2025 Earnings Call Transcript
Telix Pharmaceuticals Reports Strong Full-Year Revenue, But Shares Remain Under Pressure
Telix Pharmaceuticals Limited (TLX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Telix Pharmaceuticals Ltd. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights - TLX
Telix Pharmaceuticals Ltd. Sued for Securities Law Violations - Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights - TLX
Deadline Alert: Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 9, 2026 in Telix Pharmaceuticals Ltd. Lawsuit - TLX
TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
Class Action Filed Against Telix Pharmaceuticals Ltd. (TLX) Seeking Recovery for Investors - Contact Levi & Korsinsky
Shareholders that lost money on Telix Pharmaceuticals Ltd.(TLX) should contact Levi & Korsinsky about pending Class Action - TLX
TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm